CTIS2023-504716-15-00进行中（未招募）1 期
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Subjects with Active Psoriatic Arthritis Axial Disease - CNTO1959PSA4002
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 408
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Be at least 18 years of age, 2. Have a diagnosis of PsA for at least 6 months prior to the first administration of study intervention and meet ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria at screening., 3. Have active PsA as defined by: At least 3 swollen joints and at least 3 tender joints at screening and at baseline and C-reactive protein =0.3 mg/dL at screening from the central laboratory., 4. Have a BASDAI score of at least 4., 5. Have magnetic resonance imaging-confirmed PsA axial disease, 6. Have a spinal pain score of at least 4., 7. Have active plaque psoriasis, with at least one psoriatic plaque of =2 cm diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis., 8. Have active PsA despite previous non-biologic DMARD, apremilast, and/or NSAID therapy.
排除标准
- •1. Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis, ankylosing spondylitis/non-radiographic-axial spondyloarthritis, systemic lupus erythematosus, or Lyme disease., 10. Has or has had a serious infection or has been hospitalized or received IV antibiotics for an infection within 2 months prior to screening., 2. Has previously received any biologic treatment including, but not limited to, guselkumab, ustekinumab, secukinumab, tildrakizumab, ixekizumab, brodalumab, risankizumab or other investigative biologic treatment., 3. Has ever received a Janus kinase inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor., 4. Has received any systemic immunosuppressants within 4 weeks of the first administration of study intervention., 5. Has received apremilast within 4 weeks prior to the first administration of study intervention., 6. Has received non-biologic DMARDs other than MTX, SSZ, HCQ, LEF, within 4 weeks before the first administration of study intervention., 7. Currently has a malignancy or has a history of malignancy within 5 years prior to screening, 8. Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly., 9. Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection fungal infection, or open, draining, or infected skin wounds or ulcers.
研究者
相似试验
招募中
1 期
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive ParticipantsEUCTR2021-000465-32-BGJanssen-Cilag International NV405
进行中（未招募）
1 期
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive ParticipantsEUCTR2021-000465-32-HUJanssen-Cilag International NV405
进行中（未招募）
1 期
The Effect of Benralizumab on Structural and Lung Function Changes in Patients with Severe AsthmaEUCTR2018-003391-13-GBAstraZeneca AB81
进行中（未招募）
1 期
The Effect of Benralizumab on Structural and Lung Function Changes in Patients with Severe AsthmaEUCTR2018-003391-13-SEAstraZeneca AB81
进行中（未招募）
1 期
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive ParticipantsActive Psoriatic Arthritis Axial DiseaseMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2021-000465-32-ITJANSSEN CILAG INTERNATIONAL NV405